Du är här

2014-05-15

Santhera Pharmaceuticals Holding AG: Santhera to Present at the Bio€quity 2014 Conference

Santhera Pharmaceuticals Holding AG / Santhera to Present at the Bio€quity
2014 Conference. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Liestal, Switzerland, May 15, 2014
- Santhera Pharmaceuticals (SIX: SANN) announced today that Thomas Meier,
Chief Executive Officer of Santhera, will present at the upcoming Bio€quity
Europe 2014 Conference in Amsterdam on
Thursday, May 22, 2014, at 9.00 am. In the context of the recent filing of a
Marketing Authorization Application (MAA) in the European Union (EU) for
Raxone®in Leber's Hereditary Optic Neuropathy (LHON) and of the positive
outcome for Santhera's Phase III trial in Duchenne Muscular Dystrophy (DMD),
Dr. Meier will provide a pipeline overview and regulatory milestone and
business outlook.

Slides will be available after the presentation for download on the Company's
websitewww.santhera.comunderInvestors/Presentations
.

Now celebrating its 15thmeeting, Bio€quity Europe is the seminal industry
event for financial dealmakers looking for investor-validated life science
companies positioning themselves to attract capital, and for pharmaceutical
licensing professionals to assess top prospects. Bio€quity Europe has
showcased more than 600 leading European companies to thousands of investment
and pharma business development professionals.

* * *

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical
company focused on the development and commercialization of innovative
pharmaceutical products for the treatment of orphan mitochondrial and
neuromuscular diseases.

Santhera recently announced the re-filing of the MAA for LHON based on
additional clinical efficacy data and following pre-filing advice from EU
member states. The compound has been granted orphan drug designation in the
EU and the US. Raxone®would become the first product authorized for the
treatment of this rare, inherited disease which otherwise invariably leads to
blindness. Santhera expects a decision from the European Medicines Agency in
the first half of 2015. Earlier this year, the French National Agency for the
Safety of Medicine and Health Products (ANSM) granted a temporary
authorization for use for Raxone®in LHON patients in France based on a data
package comparable to the submitted MAA dossier.

On May 13, 2014, Santhera announced a positive outcome for its Phase III DELOS
trial in DMD. The DELOS study randomized 65 DMD patients who were 10-18 years
of age and who were not using concomitant corticosteroids. The study met the
primary endpoint, the difference between
Catena®/Raxone® and placebo in the change from baseline to week 52 in Peak
Expiratory Flow (p=0.04). Peak Expiratory Flow is a measure of respiratory
muscle strength, the decline of which is a major contributing factor to
morbidity and mortality in DMD. Catena®/Raxone®(900 mg/day) was safe and well
tolerated with adverse event rates comparable to placebo.

Santhera is collaborating with the National Institutes of Health on a
placebo-controlled Phase II clinical trial for the treatment of primary
progressive Multiple Sclerosis (ppMS), a currently untreatable disease
affecting approximately 60,000 patients in North America and 85,000 in
Europe.

Santhera holds full global patent and/or commercialization rights to all of
its clinical development programs for Catena®/Raxone®. For further
information, please visit the Company's websitewww.santhera.com.

For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier@santhera.com

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of the Company to be
materially different from those expressed or implied by such statements.
Readers should therefore not place undue reliance on these statements,
particularly not in connection with any contract or investment decision. The
Company disclaims any obligation to update these forward-looking statements.

News release BioEquity
http://hugin.info/137261/R/1785626/612371.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Globenewswire

HUG#1785626

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.